InvestorsHub Logo
Followers 20
Posts 3897
Boards Moderated 0
Alias Born 01/19/2005

Re: None

Thursday, 10/12/2017 8:38:42 AM

Thursday, October 12, 2017 8:38:42 AM

Post# of 15795
• OPKO Health (NYSEMKT:OPK) unit EirGen Pharma inks an agreement with Japan Tobacco granting it an exclusive license to develop and commercialize RAYALDEE (calcifediol) in Japan for the treatment of secondary hyperparathyroidism in non-dialysis and dialysis patients with chronic kidney disease (CKD).
• Under the terms of the deal, OPKO will receive $6M upfront, $6M upon the initiation of a Phase 2 study of RAYALDEE in U.S. dialysis patients, up to $31M in development/regulatory milestones, up to $75M in sales-based milestones and tiered, double-digit royalties on net sales. Japan Tobacco will responsible for all regulatory approvals and commercial activities in Japan.
• Shares are up 1% premarket on light volume.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OPK News